Document is current
Any future updates will be listed below
-
Authors
Ranti, Juha https://orcid.org/0000-0002-5198-2847
Jamalzadeh, Sanaz https://orcid.org/0000-0002-6425-9455
Mäkelä, Eleonora https://orcid.org/0009-0006-9564-3966
Vikkula, Johanna https://orcid.org/0000-0002-5750-6120
Havula, Essi https://orcid.org/0000-0002-9253-5816
Luopajärvi, Sari https://orcid.org/0009-0004-9370-2569
Lindström, Vesa https://orcid.org/0000-0001-5724-9120
-
Funding
Funding for this research was provided by:
Johnson & Johnson
- License Information
-
More Information
Article History
Received: 10 June 2025
Accepted: 20 August 2025
First Online: 19 September 2025
Declarations
:
: The study was approved by the Finnish Social and Health data permit authority Findata (THL/4633).
: According to the Finnish Act on Secondary use of health and social data (552/2019), no patient consent was required.
: SJ, EH, and JV are employees of Medaffcon Oy. EM is employed by Johnson & Johnson. VL has received honoraria from AbbVie, AstraZeneca, Johnson & Johnson, SL from Abbvie and Johnson & Johnson, and JR from AbbVie, Astra-Zeneca, Beigene and Johnson & Johnson. Medaffcon provided support for planning the study, analyzing the data and interpretation of the results, drafting the manuscript, and medical writing.
